By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

AB Science 

3, Avenue George V

Paris    75008  France
Phone: 33-(0)1-47200014 Fax: 33-(0)1-47202411


SEARCH JOBS


Industry
Pharmaceutical






Company News
AB Science (AB.PA): Initiation Of A New Phase 3 Study With Masitinib In Prostate Cancer, Following Encouraging Survival Results Obtained In A Phase 2 Study 2/21/2014 8:51:42 AM
AB Science (AB.PA): Initiation Of A New Phase 3 Study With Masitinib In Prostate Cancer, Following Encouraging Survival Results Obtained In A Phase 2 Study 2/20/2014 8:58:25 AM
AB Science (AB.PA) Announces Initiation Of A New Phase 3 Study In Oncology With Masitinib In Patients With Metastatic Colorectal Cancer 12/3/2013 9:46:01 AM
AB Science (AB.PA): Final Results Of Phase 3 Mastocytosis Study Expected By End Of 2014 11/12/2013 1:36:49 PM
AB Science (AB.PA): Masitinib Successfully Passes Futility Analysis in Pivotal Clinical Study in Mastocytosis 11/11/2013 11:30:16 AM
AB Science (AB.PA) Release: Masitinib is Being Investigated in the Treatment of Amyotrophic Lateral Sclerosis (ALS) 11/5/2013 9:53:45 AM
AB Science (AB.PA) and Its Partners Receive EUR 8.6 Million as Part of a Project Supported by Bpifrance in Alzheimer's Disease 7/23/2013 6:58:33 AM
AB Science (AB.PA): Launch of a Phase 3 Clinical Trial in Alzheimer's Disease 5/20/2013 11:28:38 AM
AB Science (AB.PA): 2012 Annual Financial Results and 2013 First Quarter Revenue 4/29/2013 12:03:47 PM
AB Science (AB.PA) Reports Phase 3 Study Results of Masitinib in Combination With Gemzar® for Treatment of Pancreatic Cancer 10/31/2012 8:36:40 AM
123
//-->